Welcome to our dedicated page for Aardvark Therapeutics SEC filings (Ticker: AARD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aardvark Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing small-molecule therapies for metabolic diseases. Recent 8-K reports cover financial results, pipeline and business updates, ARD-101 HERO trial disclosures in Prader-Willi Syndrome, ARD-201 obesity program updates, clinical protocol matters, and corporate presentation materials.
The filing record also includes capital-structure disclosures tied to a shelf registration statement and equity distribution agreement, governance and executive-transition matters, compensatory arrangements, and the role of Ardia Therapeutics as a wholly owned subsidiary supporting Aardvark's dermatology pipeline.
Aardvark Therapeutics filed an 8-K announcing it hosted an investor webinar on November 5, 2025 to review its ARD-101 and ARD-201 programs and its ObesityWeek 2025 presentations. The slide deck used is posted on the company’s website and is filed as Exhibit 99.1. The presentation is current as of November 5, 2025, and the company disclaims any obligation to update the material.
Aardvark Therapeutics (AARD) furnished an update under Regulation FD about new scientific disclosures at ObesityWeek 2025. The company presented two posters: “TAS2R Agonist ARD-101 Attenuates Weight Gain in Mice and Reduces Hunger in Adults with Obesity” and “An Isoflavonoid Modulator of Oxidative Metabolism with Therapeutic Potential in Obesity and Diabetes.” It also announced an investor webinar on November 5, 2025 covering ARD-101, ARD-201, and the conference data.
The materials are provided as Exhibits 99.1, 99.2, and 99.3 and are furnished, not filed, under the Exchange Act.
Aardvark Therapeutics (AARD) reported an insider transaction. On 10/15/2025, the CEO, who is also a Director and 10% Owner, exercised 1,229 stock options (transaction code M) at $4.24 and acquired 1,229 common shares.
Following the transaction, beneficial ownership was 1,544,613 shares held directly and 1,474,028 shares held indirectly by spouse. The option award shows 40,566 derivative securities beneficially owned after the event, with an expiration date of 07/20/2034.
The filing notes a vesting schedule: 1/48th of the original option vested on 07/27/2024, with 1/48th vesting monthly thereafter, subject to continuous service.
Aardvark Therapeutics (AARD) reported an insider option exercise by its Chief Operating Officer. On 10/15/2025, the officer exercised stock options (code M) to acquire 1,250 shares of common stock at an exercise price of $4.24 per share, held directly. Following the transaction, 40,052 derivative securities (stock options) remained beneficially owned.
The option carries an expiration date of 07/20/2034. Per the footnote, 1/48th vested on 07/27/2024 and continues vesting in equal monthly installments, subject to continuous service.
Aardvark Therapeutics, Inc. reported that it has reached alignment with the U.S. Food and Drug Administration on a protocol amendment to its Phase 3 HERO trial of ARD-101 for treating hyperphagia associated with Prader-Willi Syndrome.
The amendment lowers the minimum age for trial eligibility from 13 to 10 years old, allowing younger patients with this condition to participate in the Phase 3 study. The company announced this change in a press release dated October 8, 2025, which is included as an exhibit to the report.
Aardvark Therapeutics CEO and director Tien-Li Lee reported open-market purchases of Aardvark (AARD) common stock on 09/15/2025. The Form 4 shows two purchase transactions: 6,500 shares at a weighted-average price of $9.5106 and 3,500 shares at a weighted-average price of $9.9442. Following these transactions, the reporting person beneficially owned 1,543,384 shares directly and a further 1,474,028 shares indirectly through a spouse. The filing lists no derivative transactions. Footnotes disclose that each reported price is a weighted average from multiple trades within the stated price ranges.
Aardvark Therapeutics (AARD) filed a Form 144 to notify a proposed sale of 10,360 common shares by an affiliate through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $93,413.01 and an approximate sale date of 09/15/2025. The filing shows these shares were acquired from the issuer in a private transaction on 05/16/2019 for cash. The company reports 21,696,893 shares outstanding, which provides context for the size of the proposed sale relative to the float.
The filing also discloses recent sales by VICKERS VENT GLB DEEP-TECH FND I LP of 20,000 shares on 09/02/2025 for gross proceeds of $170,118.00 and 27,691 shares on 08/28/2025 for gross proceeds of $241,565.21. The notice includes the standard signer representation that no undisclosed material adverse information is known to the seller.
Nelson Sun, Chief Financial Officer of Aardvark Therapeutics (AARD), reported an insider purchase of 6,000 shares of the company's common stock at a weighted average price of $8.0733 per share, increasing his beneficial ownership to 105,484 shares.
The filing notes the reported price is a weighted average from multiple trades executed between $8.00 and $8.20 per share, and the reporting person offers to provide details on the per-trade breakdown upon request. This Form 4 documents a direct acquisition by an executive, indicating a personal purchase rather than a derivative transaction.
Form 144 notice for Aardvark Therapeutics, Inc. (AARD) reports a proposed sale of 20,000 common shares through Morgan Stanley Smith Barney valued at $170,118, with an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired from the issuer on 05/16/2019 in a private acquisition and were paid in cash. The filer also disclosed a sale of 27,691 common shares on 08/28/2025 generating $241,565.21 in gross proceeds. The filer affirms no undisclosed material adverse information.
Aardvark Therapeutics insider form 4 reports the CEO and director, Lee Tien-Li, acquired 17,209 shares on 08/28/2025 through the exercise/transfer of derivative awards at a reported price of $4.24 per share. After the transaction, Mr. Lee directly beneficially owns 1,513,384 shares and indirectly beneficially owns 1,474,028 shares through his spouse, for combined disclosure-level holdings shown on the form. The filing lists a related stock option covering 17,209 shares with an expiration date of 07/20/2034 and references a vesting schedule (1/48th monthly starting 07/27/2024). The form is signed by an attorney-in-fact on 08/29/2025.